다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The Korean journal of internal medicine : KJIM, v.33 no.2, 2018년, pp.256 - 276
Cho, Sung-Yeon (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea) , Lee, Hyeon-Jeong (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea) , Lee, Dong-Gun (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea)
AI-Helper
Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidit...
1 Lee DG Common infectious diseases in hematopoietic stem cell transplant recipients Korean J Med 2013 84 158 167
2 Wingard JR Hsu J Hiemenz JW Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology Hematol Oncol Clin North Am 2011 25 101 116 21236393
3 Tomblyn M Chiller T Einsele H Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Biol Blood Marrow Transplant 2009 15 1143 1238 19747629
4 Safdar A Armstrong D Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects Clin Infect Dis 2011 53 798 806 21890754
5 Lee JW Kim CC The activity of hematopoietic stem cell transplantation in Korea Bone Marrow Transplant 2008 42 Suppl 1 S92 S95 18724315
6 Yoo JH Lee DG Choi SM Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea Bone Marrow Transplant 2004 34 497 504 15286689
7 Park SH Choi SM Lee DG Current trends of infectious complications following hematopoietic stem cell transplantation in a single center J Korean Med Sci 2006 21 199 207 16614501
8 Kim SH Kee SY Lee DG Infectious complications following allogeneic stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens Transpl Infect Dis 2013 15 49 59 22998745
9 Bosch M Khan FM Storek J Immune reconstitution after hematopoietic cell transplantation Curr Opin Hematol 2012 19 324 335 22517587
10 Seggewiss R Einsele H Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update Blood 2010 115 3861 3868 20215642
11 Ogonek J Kralj Juric M Ghimire S Immune reconstitution after allogeneic hematopoietic stem cell transplantation Front Immunol 2016 7 507 27909435
12 Dropulic LK Lederman HM Overview of infections in the immunocompromised host Hayden RT Carroll KC Tang YW Wolk DM Diagnostic Microbiology of the Immunocompromised Host 1st ed Washington, DC ASM Press 2009 3 43
13 Lee DG Kim SH Kim SY Evidence-based guidelines for empirical therapy of neutropenic fever in Korea Korean J Intern Med 2011 26 220 252 21716917
14 Sahin U Toprak SK Atilla PA Atilla E Demirer T An overview of infectious complications after allogeneic hematopoietic stem cell transplantation J Infect Chemother 2016 22 505 514 27344206
15 Freifeld AG Bow EJ Sepkowitz KA Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 2011 52 e56 e93 21258094
16 EORTC International Antimicrobial Therapy Cooperative Group Gram-positive bacteraemia in granulocytopenic cancer patients Eur J Cancer 1990 26 569 574 2144743
17 Klastersky J Science and pragmatism in the treatment and prevention of neutropenic infection J Antimicrob Chemother 1998 41 Suppl D 13 24
18 Mikulska M Viscoli C Orasch C Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients J Infect 2014 68 321 331 24370562
19 Jun HX Zhixiang S Chun W Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever Int J Antimicrob Agents 2005 26 Suppl 2 S128 S132 16253480
20 Choi SM Lee DG Park YH Infections in patients with acute leukemia: comparison of induction chemotherapy group and reinduction chemotherapy group Infect Chemother 2003 35 78 85
21 Kim HB Park SW Kim US Infections in patients with acute leukemia (1993-1996) Korean J Hematol 1999 34 359 365
22 Kwon JC Kim SH Choi JK Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center Infect Chemother 2013 45 51 61 24265950
23 Hammarstrom V Pauksen K Svensson H Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients Transplantation 2000 69 1582 1586 10836366
24 Gustinetti G Mikulska M Bloodstream infections in neutropenic cancer patients: a practical update Virulence 2016 7 280 297 27002635
25 Gudiol C Bodro M Simonetti A Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients Clin Microbiol Infect 2013 19 474 479 22524597
26 Kim SH Kwon JC Choi SM Escherichia coli and Klebsiella pneumoniaei bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome Ann Hematol 2013 92 533 541 23161391
27 Prabhash K Medhekar A Ghadyalpatil N Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern Indian J Cancer 2010 47 184 188 20448384
28 Girmenia C Rossolini GM Piciocchi A Infections by carbapenem-resistant Klebsiella pneumoniaei in SCT recipients: a nationwide retrospective survey from Italy Bone Marrow Transplant 2015 50 282 288 25310302
29 Gedik H Simsek F Kanturk A Bloodstream infections in patients with hematological malignancies: which is more fatal. Cancer or resistant pathogens? Ther Clin Risk Manag 2014 10 743 752 25258539
30 Giannella M Trecarichi EM De Rosa FG Risk factors for carbapenem-resistant Klebsiella pneumoniaei bloodstream infection among rectal carriers: a prospective observational multicentre study Clin Microbiol Infect 2014 20 1357 1362 24980276
31 Kim SB Min YH Cheong JW Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients Scand J Infect Dis 2014 46 81 88 24325335
32 Cho SY Lee DG Choi SM Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study BMC Infect Dis 2013 13 504 24164924
33 Bow EJ Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients Curr Opin Infect Dis 2011 24 545 553 22001945
34 Cullen M Baijal S Prevention of febrile neutropenia: use of prophylactic antibiotics Br J Cancer 2009 101 Suppl 1 S11 S14 19756000
35 Neumann S Krause SW Maschmeyer G Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol 2013 92 433 442 23412562
36 Kanafani ZA Mehio-Sibai A Araj GF Kanaan M Kanj SS Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon Am J Infect Control 2005 33 326 332 16061138
37 Lautenbach E Patel JB Bilker WB Edelstein PH Fishman NO Extended-spectrum beta-lactamase-producing Escherichia coli and Pseudomonas aeruginosa: risk factors for infection and impact of resistance on outcomes Clin Infect Dis 2001 32 1162 1171 11283805
38 Colodner R Rock W Chazan B Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients Eur J Clin Microbiol Infect Dis 2004 23 163 167 14986159
39 Craig M Cumpston AD Hobbs GR Devetten MP Sarwari AR Ericson SG The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit Bone Marrow Transplant 2007 39 477 482 17322937
40 Cumpston A Craig M Hamadani M Abraham J Hobbs GR Sarwari AR Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit Transpl Infect Dis 2013 15 142 149 23279656
41 von Baum H Sigge A Bommer M Moxifloxacin prophylaxis in neutropenic patients J Antimicrob Chemother 2006 58 891 894 16880172
42 Mikulska M Averbuch D Tissot F Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines J Infect 2018 76 20 37 29079323
43 Gea-Banacloche J Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies Hematology Am Soc Hematol Educ Program 2013 2013 414 422 24319213
44 Averbuch D Orasch C Cordonnier C European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia Haematologica 2013 98 1826 1835 24323983
45 Kurosawa M Yonezumi M Hashino S Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies Int J Hematol 2012 96 748 757 23111539
46 Pagano L Caira M Nosari A Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne Clin Infect Dis 2007 45 1161 1170 17918077
47 Choi JK Cho SY Yoon SS Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of "RISK" Study Biol Blood Marrow Transplant 2017 23 1773 1779 28668492
48 National Comprehensive Cancer Network National Comprehensive Cancer Network clinical practice guidelines in oncology: prevention and treatment of cancer-related infections. Version 1. 2018 [Internet] Fort Washington (PA) NCCN c2018 [cited 2018 Feb 12]. Available from: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx
49 Leventakos K Lewis RE Kontoyiannis DP Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010 50 405 415 20047485
50 Kullberg BJ Arendrup MC Invasive candidiasis N Engl J Med 2015 373 1445 1456 26444731
51 Pappas PG Kauffman CA Andes DR clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America Clin Infect Dis 2016 62 e1 e50 26679628
52 Wingard JR Hsu J Hiemenz JW Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology Infect Dis Clin North Am 2010 24 257 272 20466269
53 Marchetti O Lamoth F Mikulska M ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients Bone Marrow Transplant 2012 47 846 854 21927034
54 Hsu LY Lee DG Yeh SP Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study Clin Microbiol Infect 2015 21 594
55 Bergeron A Porcher R Sulahian A The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies Blood 2012 119 1831 1837 22010103
56 Kim SH Lee DG Kwon JC Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a Korean population Infect Chemother 2013 45 406 414 24475354
57 Maertens JA Raad II Marr KA Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial Lancet 2016 387 760 769 26684607
58 Tissot F Agrawal S Pagano L ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Haematologica 2017 102 433 444 28011902
59 Michallet M Ito JI Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation J Clin Oncol 2009 27 3398 3409 19487382
60 Maertens J Marchetti O Herbrecht R European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3. 2009 update Bone Marrow Transplant 2011 46 709 718 20661235
61 Kim SB Cho SY Lee DG Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: a 5-year retrospective cohort study Med Mycol 2017 55 237 245 27562861
62 Park SY Yoon JA Kim SH Voriconazole-refractory invasive aspergillosis Korean J Intern Med 2017 32 805 812 28835093
63 Cho SY Lee DG Choi JK Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species Medicine (Baltimore) 2017 96 e8841 29245249
64 Maertens J Cesaro S Maschmeyer G ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients J Antimicrob Chemother 2016 71 2397 2404 27550992
65 Lee HY Kang HS Lee HY Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice Korean J Intern Med 2017 32 478 485 27951623
66 Fan LC Lu HW Cheng KB Li HP Xu JF Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review PLoS One 2013 8 e73099 24023814
67 Lu Y Ling G Qiang C PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis J Clin Microbiol 2011 49 4361 4363 22012008
68 Alanio A Hauser PM Lagrou K ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients J Antimicrob Chemother 2016 71 2386 2396 27550991
69 Green H Paul M Vidal L Leibovici L Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials Mayo Clin Proc 2007 82 1052 1059 17803871
70 Green H Paul M Vidal L Leibovici L Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients Cochrane Database Syst Rev 2007 3 CD005590 17636808
71 Cordonnier C Cesaro S Maschmeyer G Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients J Antimicrob Chemother 2016 71 2379 2385 27550990
72 Cooley L Dendle C Wolf J Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014 Intern Med J 2014 44 1350 1363 25482745
73 Thursky KA Worth LJ Seymour JF Miles Prince H Slavin MA Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab Br J Haematol 2006 132 3 12 16371014
74 Boeckh M Geballe AP Cytomegalovirus: pathogen, paradigm, and puzzle J Clin Invest 2011 121 1673 1680 21659716
75 Ljungman P Griffiths P Paya C Definitions of cytomegalovirus infection and disease in transplant recipients Clin Infect Dis 2002 34 1094 1097 11914998
76 Ljungman P Reusser P de la Camara R Management of CMV infections: recommendations from the infectious diseases working party of the EBMT Bone Marrow Transplant 2004 33 1075 1081 15077131
77 Choi SM Lee DG Park SH Characteristics of cytomegalovirus diseases among hematopoietic stem cell transplant recipients: a 10-year experience at an university hospital in Korea Infect Chemother 2009 41 9 19
78 Jeon S Lee WK Lee Y Lee DG Lee JW Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation Ophthalmology 2012 119 1892 1898 22657564
79 Teira P Battiwalla M Ramanathan M Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis Blood 2016 127 2427 2438 26884374
80 Kim T Lee YM Lee SO Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy Korean J Intern Med 2016 31 961 970 27055664
81 Lee HY Rhee CK Choi JY Lee HY Lee JW Lee DG Diagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignancies Oncotarget 2017 8 39736 39745 28061469
82 Choi SM Lee DG Lim J Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients J Korean Med Sci 2009 24 571 578 19654935
83 Choi SM Lee DG Choi JH Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea Int J Hematol 2005 81 69 74 15717693
84 Cho BS Yahng SA Kim JH Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy Ann Hematol 2013 92 497 504 23180439
85 Marty FM Ljungman P Chemaly RF Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation N Engl J Med 2017 377 2433 2444 29211658
86 Khanna R. Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management. J Clin Microbiol 2018 Jan 17 [Epub]. https://doi.org/10.1128/JCM.02009-17
87 Yong MK Cameron PU Slavin M Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation J Infect Dis 2017 215 1684 1694 28431019
88 Jung J Lee HJ Kim SM Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients J Clin Virol 2017 87 5 11 27984766
89 Kim SH Lee HS Lee HJ Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study Korean J Intern Med 2017 32 900 909 28830137
90 Kim SH Lee HJ Kim SM Diagnostic usefulness of cytomegalovirus (CMV)-specific T cell immunity in predicting CMV infection after kidney transplantation: a pilot proof-of-concept study Infect Chemother 2015 47 105 110 26157588
91 Lee H Park KH Ryu JH Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients PLoS One 2017 12 e0189488 29232714
92 Han SH Immunological prediction of cytomegalovirus (CMV) replication risk in solid organ transplantation recipients: approaches for regulating the targeted anti-CMV prevention strategies Infect Chemother 2017 49 161 175 29027383
93 Park SH Choi SM Lee DG Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin Transpl Infect Dis 2009 11 413 423 19708893
94 Gilbert C Roy J Belanger R Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients Antimicrob Agents Chemother 2001 45 3669 3671 11709367
95 Hantz S Garnier-Geoffroy F Mazeron MC Drug-resistant cytomegalovirus in transplant recipients: a French cohort study J Antimicrob Chemother 2010 65 2628 2640 20961907
96 Shmueli E Or R Shapira MY High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation J Infect Dis 2014 209 557 561 23983215
97 El Chaer F Shah DP Chemaly RF How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients Blood 2016 128 2624 2636 27760756
98 Kang CI Choi CM Park TS Lee DJ Oh MD Choe KW Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea Int J Infect Dis 2008 12 245 247 17950022
99 Kim YH Hwang JY Lee KM Seroepidemiologic survey of varicella-zoster virus in Korean adults using glycoprotein enzyme immunoassay and fluorescent antibody to membrane antigen test Ann Dermatol 2011 23 39 43 21738361
100 Choi WS Noh JY Huh JY Seroprevalence of varicella-zoster virus in Korea J Med Virol 2010 82 2123 2126 20981803
101 Styczynski J Reusser P Einsele H Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia Bone Marrow Transplant 2009 43 757 770 19043458
102 Kim DH Kumar D Messner HA Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation Clin Transplant 2008 22 770 779 18707605
103 Seo HM Kim YS Bang CH Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis Antiviral Res 2017 140 106 115 28132866
104 Park SH Choi SM Lee DG Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea J Korean Med Sci 2006 21 259 264 16614511
105 Styczynski J van der Velden W Fox CP Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines Haematologica 2016 101 803 811 27365460
106 Kim YJ Kim DW Lee DG Human herpesvirus-6 as a possible cause of encephalitis and hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation Leukemia 2002 16 958 959 11986964
107 Dropulic LK Jones RJ Polyomavirus BK infection in blood and marrow transplant recipients Bone Marrow Transplant 2008 41 11 18 17952131
108 Ison MG Adenovirus infections in transplant recipients Clin Infect Dis 2006 43 331 339 16804849
109 Knowles WA Pipkin P Andrews N Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 J Med Virol 2003 71 115 123 12858417
110 Kean JM Rao S Wang M Garcea RL Seroepidemiology of human polyomaviruses PLoS Pathog 2009 5 e1000363 19325891
111 Egli A Infanti L Dumoulin A Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors J Infect Dis 2009 199 837 846 19434930
112 Rinaldo CH Tylden GD Sharma BN The human polyomavirus BK (BKPyV): virological background and clinical implications APMIS 2013 121 728 745 23782063
113 Cesaro S Dalianis T Hanssen Rinaldo C ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients J Antimicrob Chemother 2018 73 12 21 29190347
114 Erard V Kim HW Corey L BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients Blood 2005 106 1130 1132 15845896
115 Cesaro S Tridello G Pillon M A prospective study on the predictive value of plasma BK virus-DNA load for hemorrhagic cystitis in pediatric patients after stem cell transplantation J Pediatric Infect Dis Soc 2015 4 134 142 26407413
116 Gaziev J Paba P Miano R Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir Biol Blood Marrow Transplant 2010 16 662 671 20026413
117 Koskenvuo M Dumoulin A Lautenschlager I BK polyomavirus-associated hemorrhagic cystitis among pediatric allogeneic bone marrow transplant recipients: treatment response and evidence for nosocomial transmission J Clin Virol 2013 56 77 81 22999487
118 Kwon HJ Kang JH Lee JW Chung NG Kim HK Cho B Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience Transpl Infect Dis 2013 15 569 574 24028353
119 Faraci M Cuzzubbo D Lanino E Low dosage cidofovir without probenecid as treatment for BK virus hamorrhagic cystitis after hemopoietic stem cell transplant Pediatr Infect Dis J 2009 28 55 57 19057462
120 Ganguly N Clough LA Dubois LK Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach Transpl Infect Dis 2010 12 406 411 20487411
121 Lee SS Ahn JS Jung SH Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation Korean J Intern Med 2015 30 212 218 25750563
122 Savona MR Newton D Frame D Levine JE Mineishi S Kaul DR Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant Bone Marrow Transplant 2007 39 783 787 17438584
123 Tylden GD Hirsch HH Rinaldo CH Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells Antimicrob Agents Chemother 2015 59 3306 3316 25801568
124 Weigt SS Gregson AL Deng JC Lynch JP 3rd Belperio JA Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients Semin Respir Crit Care Med 2011 32 471 493 21858751
125 Kumar D Humar A Respiratory viral infections in transplant and oncology patients Infect Dis Clin North Am 2010 24 395 412 20466276
126 Ahn MY Choi SH Chung JW Kim HR Utilization of the respiratory virus multiplex reverse transcription-polymerase chain reaction test for adult patients at a Korean tertiary care center Korean J Intern Med 2015 30 96 103 25589841
127 Hong KW Choi SM Lee DG Lower respiratory tract diseases caused by common respiratory viruses among stem cell transplantation recipients: a single center experience in Korea Yonsei Med J 2017 58 362 369 28120567
128 Shah JN Chemaly RF Management of RSV infections in adult recipients of hematopoietic stem cell transplantation Blood 2011 117 2755 2763 21139081
129 Hirsch HH Martino R Ward KN Boeckh M Einsele H Ljungman P Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus Clin Infect Dis 2013 56 258 266 23024295
130 Chemaly RF Hanmod SS Rathod DB The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation Blood 2012 119 2738 2745 22246027
131 Nichols WG Corey L Gooley T Davis C Boeckh M Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome Blood 2001 98 573 578 11468152
132 Ljungman P de la Camara R Perez-Bercoff L Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients Haematologica 2011 96 1231 1235 21546495
133 Schnell D Mayaux J de Bazelaire C Risk factors for pneumonia in immunocompromised patients with influenza Respir Med 2010 104 1050 1056 20181467
134 Engelhard D Mohty B de la Camara R Cordonnier C Ljungman P European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN Transpl Infect Dis 2013 15 219 232 23363310
135 Parody R Rabella N Martino R Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies Am J Hematol 2007 82 807 811 17563077
136 Gutman JA Peck AJ Kuypers J Boeckh M Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases Bone Marrow Transplant 2007 40 809 811 17704788
137 Dignan FL Clark A Aitken C BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation Br J Haematol 2016 173 380 393 27060988
138 Baek JH Seo YB Choi WS Guideline on the prevention and control of seasonal influenza in healthcare setting Korean J Intern Med 2014 29 265 280 24648817
139 Choi WS Lee J Lee HY Clinical practice guideline for antiviral treatment and chemoprophylaxis of seasonal influenza Infect Chemother 2012 44 233 249
140 von Lilienfeld-Toal M Berger A Christopeit M Community acquired respiratory virus infections in cancer patients-guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology Eur J Cancer 2016 67 200 212 27681877
141 Shah DP Ghantoji SS Ariza-Heredia EJ Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections Blood 2014 123 3263 3268 24700783
142 de Fontbrune FS Robin M Porcher R Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation Clin Infect Dis 2007 45 1019 1024 17879919
143 DeVincenzo JP Whitley RJ Mackman RL Oral GS-5806 activity in a respiratory syncytial virus challenge study N Engl J Med 2014 371 711 722 25140957
144 Choi WS Baek JH Seo YB Severe influenza treatment guideline Korean J Intern Med 2014 29 132 147 24574848
145 Bumbacea D Arend SM Eyuboglu F The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement Eur Respir J 2012 40 990 1013 22496318
146 Lee HJ Lee DG Choi SM The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: high incidence compared with general population PLoS One 2017 12 e0173250 28278166
147 Fan WC Liu CJ Hong YC Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study Int J Tuberc Lung Dis 2015 19 58 64 25519791
148 Al-Anazi KA Al-Jasser AM Alsaleh K Infections caused by mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation Front Oncol 2014 4 231 25207262
149 Lee J Lee MH Kim WS Tuberculosis in hematopoietic stem cell transplant recipients in Korea Int J Hematol 2004 79 185 188 15005349
150 Tsigrelis C Ljungman P Vaccinations in patients with hematological malignancies Blood Rev 2016 30 139 147 26602587
151 Chong PP Avery RK A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients Clin Ther 2017 39 1581 1598 28751095
152 Lee DG Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea Infect Chemother 2013 45 272 282 24396628
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.